ストックスクリーナーアプリを入手
8.20
3.87%
-0.33
アフターアワーズ：
8.25
0.05
+0.61%
前日終値:
$8.53
開ける：
$8.67
24時間の取引高:
112.15K
Relative Volume:
1.16
時価総額：
$210.04M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-5.8156
EPS:
-1.41
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
+11.11%
1か月 パフォーマンス:
+22.21%
6か月 パフォーマンス:
+8.75%
1年 パフォーマンス:
+24.05%
1日の値動き範囲:
$8.0001
$8.70
1週間の範囲:
$7.22
$8.70
52週間の値動き範囲:
$5.34
$11.52
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.20 | 218.50M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Will Nuvectis Pharma Inc. stock benefit from commodity prices2026 world cup usa national team group stage young talents transition play group prediction preview - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b - GlobeNewswire
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
Will Nuvectis Pharma Inc. stock attract more institutional investors2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Will Nuvectis Pharma Inc. stock split attract more investors2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Published on: 2025-11-30 11:27:46 - BỘ NỘI VỤ
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - marketscreener.com
Nuvectis Pharma to Host a Virtual Key Opinion Leader - GlobeNewswire
Trading the Move, Not the Narrative: (NVCT) Edition - news.stocktradersdaily.com
How Nuvectis Pharma Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nuvectis Pharma Inc. stock trendline breakdownPortfolio Risk Summary & Stock Market Timing Techniques - newser.com
How currency fluctuations impact Nuvectis Pharma Inc. stockEarnings Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):